Form 4: Corcept Therapeutics Director James N. Wilson Reports Gift of Shares and Beneficial Ownership
SEC Form 4 Filing
Director James N. Wilson reports a gift of 7,800 common stock shares and updates beneficial ownership in Corcept Therapeutics.
Summary
- On January 27, 2025, James N. Wilson, a director of Corcept Therapeutics, reported a transaction involving the company's common stock.
- Wilson gifted 7,800 shares of common stock.
- Following the transaction, Wilson's indirectly held beneficial ownership includes 1,445,168 shares through the James N. Wilson and Pamela D. Wilson Trust and 901,067 shares through James and Pamela Wilson Family Partners.
- Wilson disclaims beneficial ownership of these shares except to the extent of his pecuniary interest, retaining voting power through voting agreements.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
This filing is a routine disclosure related to insider transactions and beneficial ownership, which is standard practice for publicly traded companies.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in ownership, but it is unlikely to be significant.
Key Dates
| Date | Description |
|---|---|
| 01/27/2025 | Date of transaction (gift of common stock) |
| 01/29/2025 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.